Publication:
A Post-International Gastrointestinal Cancers’ Conference (IGICC) position statements

dc.contributor.coauthorYalcin, Suayib
dc.contributor.coauthorKaseb, Ahmed Omar
dc.contributor.coauthorPeynircioglu, Bora
dc.contributor.coauthorCantasdemir, Murat
dc.contributor.coauthorHurmuz, Pervin
dc.contributor.coauthorDorul, Ahmet Bulent
dc.contributor.coauthorBozkurt, Murat Fani
dc.contributor.coauthorAbali, Huseyin
dc.contributor.coauthorAkhan, Okan
dc.contributor.coauthorSimsek, Halis
dc.contributor.coauthorSahin, Berksoy
dc.contributor.coauthorAykan, Faruk N.
dc.contributor.coauthorYucel, Idris
dc.contributor.coauthorPhilip, Philip
dc.contributor.kuauthorLaçin, Şahin
dc.contributor.kuauthorTellioğlu, Gürkan
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.kuauthorÇil, Barbaros Erhan
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.date.accessioned2024-12-29T09:38:31Z
dc.date.issued2024
dc.description.abstractHepatocellular carcinoma (HCC), the most prevalent liver tumor, is usually linked with chronic liver diseases, particularly cirrhosis. As per the 2020 statistics, this cancer ranks 6th in the list of most common cancers worldwide and is the third primary source of cancer-related deaths. Asia holds the record for the highest occurrence of HCC. HCC is found three times more frequently in men than in women. The primary risk factors for HCC include chronic viral infections, excessive alcohol intake, steatotic liver disease conditions, as well as genetic and family predispositions. Roughly 40-50% of patients are identified in the late stages of the disease. Recently, there have been significant advancements in the treatment methods for advanced HCC. The selection of treatment for HCC hinges on the stage of the disease and the patient's medical status. Factors such as pre-existing liver conditions, etiology, portal hypertension, and portal vein thrombosis need critical evaluation, monitoring, and appropriate treatment. Depending on the patient and the characteristics of the disease, liver resection, ablation, or transplantation may be deemed potentially curative. For inoperable lesions, arterially directed therapy might be an option, or systemic treatment might be deemed more suitable. In specific cases, the recommendation might extend to external beam radiation therapy. For all individuals, a comprehensive, multidisciplinary approach should be adopted when considering HCC treatment options. The main treatment strategies for advanced HCC patients are typically combination treatments such as immunotherapy and anti-VEGFR inhibitor, or a combination of immunotherapy and immunotherapy where appropriate, as a first-line treatment. Furthermore, some TKIs and immune checkpoint inhibitors may be used as single agents in cases where patients are not fit for the combination therapies. As second -line treatments, some treatment agents have been reported and can be considered.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.volume11
dc.identifier.doi10.2147/JHC.S449540
dc.identifier.eissn2253-5969
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85195117828
dc.identifier.urihttps://doi.org/10.2147/JHC.S449540
dc.identifier.urihttps://hdl.handle.net/20.500.14288/22689
dc.identifier.wos1238803700001
dc.keywordsHepatocellular carcinoma
dc.keywordsScreening
dc.keywordsImaging
dc.keywordsDiagnosis
dc.keywordsTreatment
dc.keywordsImmunotherapy
dc.keywordsTyrosine kinase inhibitors
dc.languageen
dc.publisherDOVE MEDICAL PRESS LTD
dc.sourceJournal of Hepatocellular Carcinoma
dc.subjectOncology
dc.titleA Post-International Gastrointestinal Cancers’ Conference (IGICC) position statements
dc.typeJournal article
dspace.entity.typePublication
local.contributor.kuauthorLaçin, Şahin
local.contributor.kuauthorTellioğlu, Gürkan
local.contributor.kuauthorSelçukbiricik, Fatih
local.contributor.kuauthorÇil, Barbaros Erhan

Files